

TLS Symposium on September 24, 2019 in Paris

Tertiary Lymphoid Structures in the Era of Cancer Therapies

Organizers : A. Dimberg, WH. Fridman, C Sautès-Fridman

Centre de Recherche des Cordeliers
Amphitheatre Bilski-Pasquier
15 rue de l'Ecole de Médecine, 75006, Paris

Registration required (free): http://simpleeventsignup.com/private_event/153692/badc0dc3cd
Contact: tertiary2019@yahoo.com

13h00: A Dimberg (Uppsala), C Sautès-Fridman (Paris), J Zucman-Rossi (Director of CRC)
Welcome and introduction

Session 1: TLS and the tumor microenvironment

Chairs: Chris G Mueller (Strasbourg, France), Catherine Sautès-Fridman (Paris)

13h15-13h45: Ruth Ganss (Perth, Australia)

LIGHT targeting of tumor vessels overcomes resistance to immunotherapy

13h45-14h05: Anna Dimberg (Uppsala, Sweden)

Induction of TLS and anti-tumor response in glioma

14h05-14h35: Viktor H Engelhard (Charlottesville, VA)

Role of innate and adaptive immunity in TLS formation

14h35-14h55: Karina Silina (Zurich, Switzerland)

Harnessing lymphoid neogenesis for prognosis and treatment of solid tumors

14h55-15h15: General discussion

15h15-15h55: Coffee break

Session 2: TLS as predictive and therapeutic tools

Chairs: Awen Gallimore (Cardiff, UK), Anna Dimberg (Uppsala, Sweden)

15h55-16h15: Karen Willard Gallo (Brussels, Belgium)

TLS composition and organization in breast cancers, relationship with immune activation and exhaustion

16h15-16h35: Catherine Sautès-Fridman (Cordeliers Research Centre, Paris)

B cell signatures are associated with improved survival and immunotherapy response in sarcoma patients

16h35-17h05: Beth A Helmink (Houston, TX)

Contribution of B cells in response to immune check-point blockade

17h05-17h25: Daniela Thommen (Amsterdam, The Netherlands)

TLS-CD8+T cells with predictive potential in NSCLC treated with PD-1 blockade

17h25-17h55: Adam Meilloux (Tampa, FL)

Tumor-associated TLS: gene expression profiling and their bioengineering

17h55-18h15: General discussion

18h15-18h25: W.H. Fridman (Cordeliers Research Centre, Paris) *Concluding remarks*



Bristol-Myers Squibb



Symposium prior to the 5th international cancer immunotherapy conference, Paris, Sept 25-28, 2019